article Open AccessTop 1% cited

A Randomized, Placebo-Controlled Trial of Zoledronic Acid in Patients With Hormone-Refractory Metastatic Prostate Carcinoma

JNCI Journal of the National Cancer Institute · 2002 · Vol. 94(19) · pp. 1458–1468

Fred Saad✉(Hôpital Notre-Dame)Donald M. Gleason(Centre Hospitalier de l’Université de Montréal)Robin Murray(Centre Hospitalier de l’Université de Montréal)S. Tchekmedyian(London Health Sciences Centre)P. Venner(Hôtel-Dieu de Québec)Louis Lacombe(London Health Sciences Centre)Joseph L. Chin(Centre Hospitalier de l’Université de Montréal)J. J. Vinholes(London Health Sciences Centre)J. A. Goas(Advanced Pharma)Bee‐Lian Chen(Advanced Pharma)

View via DOI Full-text PDF

Abstract

Zoledronic acid at 4 mg reduced skeletal-related events in prostate cancer patients with bone metastases.

Bone health and treatments Prostate Cancer Treatment and Research Radiopharmaceutical Chemistry and ApplicationsZoledronic acidMedicineOncologyPlaceboInternal medicineRandomized controlled trialRefractory (planetary science)Prostate carcinomaProstateUrology

MeSH terms

Zoledronic AcidAdenocarcinomaAgedAntineoplastic AgentsBone NeoplasmsBone ResorptionDiphosphonatesDose-Response Relationship, DrugDouble-Blind MethodHumansImidazolesInfusions, IntravenousMaleNeoplasms, Hormone-DependentProstatic Neoplasms

Citations

1,654

FWCI

41.48

field-weighted impact

References

Percentile

100%

vs. same field & year

Citations per year

Cited by

Frequency and Risk Factors Associated With Osteonecrosis of the Jaw in Cancer Patients Treated With Intravenous Bisphosphonates